Merck KGaA Reports Strong Q3 Results and Raises Full-Year Guidance
Underlying earnings and sales exceeded expectations across all businesses, according to J.P. Morgan analysts.
Story updates
08:32:20 AM UTC
SquawkNews
Merck KGaA reported strong third-quarter performance, with both revenue and operating profit surpassing analyst expectations. Driven by this positive operational momentum, favorable currency effects, and the anticipated completion of the Bio-Techne acquisition in December, the company has raised its full-year 2026 guidance for the third consecutive time. The updated forecast now projects full-year net sales to range between $23.84 billion and $24.29 billion, an increase from the previous guidance of $23.29 billion to $24.18 billion. This marks the third time in 2026 that the company has adjusted its annual outlook upward.
Germany's Merck KGaA reported strong third-quarter results, with underlying earnings ahead of estimates and sales coming in better than anticipated across all businesses, J.P. Morgan analysts write. The German life-science and chemical group also raised its full-year guidance. While a guidance incr…